Clinical trials
Recruiting Attention Deficit Disorder with Hyperactivity trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
99 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 9 |
| 2023 | 5 |
| 2024 | 22 |
| 2025 | 33 |
| 2026 | 20 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 99 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Children's Hospital Medical Center, Cincinnati | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| China Medical University Hospital | 2 |
| Chinese University of Hong Kong | 2 |
| Florida State University | 2 |
| Francisco Gonzalez-Lima, PhD | 2 |
| Massachusetts General Hospital | 2 |
| University Hospital Bispebjerg and Frederiksberg | 2 |
| University of California, Davis | 2 |
| University of Pittsburgh | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Attention Deficit Disorder with Hyperactivity | 99 |
| Autism Spectrum Disorder | 8 |
| Autistic Disorder | 5 |
| Neurodevelopmental Disorders | 5 |
| Parasomnias | 4 |
| Substance-Related Disorders | 4 |
| Anxiety Disorders | 3 |
| Brain Injuries, Traumatic | 3 |
| Mental Disorders | 3 |
| Oppositional Defiant Disorder | 3 |
Trials
Showing 1 to 25 of 99. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.